

CURRICULUM VITAE**A. Personal Information:**

Name	Richard Sposto, Ph. D.
Business Address	Director, Biostatistics/Bioinformatics Children's Center for Cancer and Blood Diseases Children's Hospital Los Angeles 4650 Sunset Boulevard, Mail Stop #54 Los Angeles, California, 90027-6016
Business Phone	323-361-8582
Business Fax	323-361-2988
Home Address	916 E. Walnut Ave. Burbank, CA, 91501
Citizenship	U.S.A.
E-mail	rsposto@chla.usc.edu sposto@usc.edu

B. Education:

High School	Warren High School, Downey, CA, 1969
University	U.C.L.A., Los Angeles, CA, B.A. Mathematics, 1974 U.C.L.A., Los Angeles, CA, M.S. Biostatistics, 1977 U.C.L.A., Los Angeles, CA, Ph.D. Biostatistics, 1981

C. Professional background:**Academic Appointments**

Professor of Research, Preventive Medicine and Pediatrics (CHLA), Keck School of Medicine of USC , Los Angeles, California, 2/2006-Present.

Associate Professor of Research, Preventive Medicine and Pediatrics (CHLA), Keck School of Medicine of USC, Los Angeles, California, 9/2004-1/2006

Associate Professor of Research, Department of Preventive Medicine, Keck School of Medicine of USC , Los Angeles, California, 1994-9/2004.

Assistant Professor of Research, Department of Preventive Medicine, U.S.C. School of Medicine, and Childrens Cancer Study Group, Los Angeles, California, 1981-1988.

Administrative Appointments

Director Biostatistics/Bioinformatics, Center for Cancer and Blood Disease, Children's Hospital Los Angeles, Los Angeles, California, 9/2004-Present

Group Statistician and Principal Investigator, Statistics and Data Center, Children's Oncology Group, Arcadia, California, 2002-2004

Associate Group Statistician, Statistics and Data Center, Children's Oncology Group, Arcadia, California, 2000-2002

Specific teaching/mentoring activities

- Co-mentor (with Paul Gaynon, M.D.) for Filipe Arce, M.D. fellowship research project entitled "Variation in Outcome in Pediatric Acute Lymphoblastic Leukemia (ALL) in U.S. Hospitals" 2005-2007
- Co-mentor (with Smita Bhatia, M.D. M.Ph., City of Hope) for Saro Armenian, M.D. fellowship research project regarding late cardiac compromise in cancer survivors who have undergone hematopoietic stem cell transplant (HSCT) 2006-2008.
- Biostatistical advisor to John van Doorninck, M.D. fellowship research project "A clinico-pathologic study of stem cell marker expression in Ewing's sarcoma" (Elizabeth Lawlor, M.D., Mentor) 2006-2008
- Biostatistical advisor to Richard Ko, M.D., for fellowship research project "Thromboelastographic Detection of Hypercoagulability in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia" (Guy Young, MD, Mentor) 2008-present
- Biostatistical advisor to Tom Davidson, M.D. for fellowship research project "Insulin-Like Growth Factor Binding Protein-2 in Medulloblastoma : Friend or Foe? (Anat Erdreich-Epstein, M.D. Ph.D.) 2008-present
- Biostatistical advisor to Nathan Robison, M.D., for fellowship research project "Forkhead box G1 expression and risk classification in medulloblastoma" (Shahab Asgharazdeh, M.D., Mentor) 2008-2009
- Co-chair (with Stanley P. Azen, Ph.D.) for Ying Wang, Ph.D student in the Division of Biometry, Department of Preventive Medicine, re Ph.D. research "Non-parametric Statistical Methods in Estimating Survival Distribution for Two Stage Design Randomized Clinical Trials" 2007-2009.
- Biostatistical advisor for Tanja Gruber, M.D., for fellowship research project "Activation Induced Cytidine Deaminase as a Causitive Agent of Therapy Resistance in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia" 2007-2009
- Biostatistical Advisor to Raj Venkatramani, M.D., for fellowship research project "A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (vit-b) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin". 2009-Present
- Co-Mentor to Weili Sun, M.D., Ph.D., for SC-CTSI KL2 Mentored Research Career Development Award Review Committee for project entitled "A Study of 5-Azacytidine in Combination of High Dose Cytarabine and Asparaginase for Children with Relapsed or Refractory Acute Myeloid Leukemia (AML)". 2011-Present
- Topic Advisor for Jiaxiu He, Ph.D student in the Division of Biometry, Department of Preventive Medicine, re Ph.D. research on corrections for class misclassification in microarray-based risk classifiers. 2009-present
- Graduate course in Mathematical Statistics, Division of Biometry, U.S.C. Department of Preventive Medicine (1985-1986)

Graduate course in Clinical Trials Design (PM523), Division of Biometry, U.S.C. Department of Preventive Medicine (Fall 1999, 2000, 2001)

Lectures in survival analysis and Phase III design for Design and Conduct of Clinical Trials, K-24 funded lecture series, Norris Cancer Center (2001, 2002, 2004, 2005), PI: J. Weber

Lecture in survival analysis for Fellows Core Curriculum Course at CHLA (2005)

Lectures in basic statistics, clinical trials design, and survival analysis for the Educational Course for Hematology/Oncology Fellows at CHLA (2005-2009)

Lecture, "Study Design (in brief) for CHLA Clinical Research Education Series, August 1, 2006

Other

Research Scientist, Department of Statistics, Radiation Effects Research Foundation, Hiroshima City, Japan, 1988-1992

Statistician and Co-Principal Investigator, Aids Vaccine Evaluation Group Data and Statistical Center, The EMMES Corporation, Potomac, Maryland, 1992-1994

Mathematical Statistician, Office of Surveillance and Biometry, FDA Center for Devices and Radiological Health, Rockville, Maryland, 1994

D. **Society Memberships**

Professional

American Statistical Association, 1974-present

Biometrics Society, 1978-2000

American Society of Clinical Oncology, 1998-2008

Society for Clinical Trials, 1998-2001

American Associate for Cancer Research 2007-2008

International Society for Clinical Biostatistics, 2000-2002

E. **Service:**

University committees

Clinical Investigations Committee, USC/Norris Cancer Center (2000-2001, 2005-present)

Research Guidance Committee/Scholarship Oversight Committee, Division of Hematology/Oncology, Children's Hospital Los Angeles (2006-present)

Member U.S.C. Clinical and Translational Sciences Institute (CTSA), Team 2: Biomedical Informatics, Biostatistics and Research Ethics, as part of preparation for U.S.C. CTSA Application, October 2007.

Member, USC/Norris Comprehensive Cancer Center Informatics Working Group, August 2007-2009.

Member of advisory committee for the USC/CHLA/COH/Kaiser Clinical and Translational Sciences Institute (CTSA). October 2007-present.

Co-chair, USC/Norris Cancer Center Data and Safety Monitoring Committee (2010-present)

Childrens Hospital Los Angeles Cancer Committee (2005-2007)

Member, Research Council, Children's Hospital Los Angeles, 2009-2010

National Committees

Member, NCI Pediatric and Adolescent Solid Tumor Steering Committee (PASTSC), 2011-present

Member (alternate), NCI Pediatric Leukemia and Lymphoma Steering Committee (PLLSC), 2011-present

Other Committees

Children's Oncology Group Scientific Council (2002-2004)

Children's Oncology Group Executive Committee (2002-2004)

Brain Tumor Strategy Group, Children's Cancer Group, 1995-1999

Brain Tumor Core Committee, Children's Oncology Group, 1999-2004

Lymphoma Strategy Group, Children's Cancer Group, 1995-1999

Soft-tissue Sarcoma Strategy Group, Children's Cancer Group, 1995-1999

Lymphoma Core Committee, Children's Oncology Group, 1999-2001

Hodgkin's Disease Core Committee, Children's Oncology Group, 2001-2004.

Developmental Therapeutic Steering Committee, Children's Oncology Group, 2001-2002

Joint Children's Cancer Group/United Kingdom Children's Cancer Study Group, and Société Française d'Oncologie Pédiatrique Study Committee FAB LMB 96, 1995-2005. **(International)**

Data and Safety Monitoring Committee (DSMC) for the International Consortium on Low Grade Glioma (ICLGG) of the International Society of Pediatric Oncology (SIOP) for SIOP - LGG 2004 Cooperative multicenter Study for Children and adolescents with Low Grade Glioma, 2004-present. **(International)**

Data and Safety Monitoring Board (DSMB) for The Histiocyte Society, an international group physicians and scientists conducting clinical and laboratory research into the causes and treatment of histiocytosis. Inaugural statistician, 2009-present **(International)**

Numerous Children's Cancer Group and Children's Oncology Group Study committees related to specific clinical and biological research studies in Non-Hodgkin's Lymphoma, Hodgkin's Disease, CNS tumors,

Developmental Therapeutics in childhood neoplasms (1981-1988, 1995-2005)

Government Activities

U.S. Department of Defense Breast Cancer Review Panel, Clinical and Experimental Therapeutics #4, August 2000.

U.S. Department of Defense Breast Cancer Review Panel, Clinical and Experimental Therapeutics #4, August 2001.

National Cancer Institute, Committee on Common Data Elements (CDE) for Lymphomas, 2002-2003.

National Cancer Institute, Committee on Common Data Elements (CDEs) for Brain Tumors, 2002-2003.

National Cancer Institute, Committee on Common Data Elements (CDEs) for Wilm's Tumor, 2002-2003. (Chair)

National Cancer Institute, Committee on Common Data Elements (CDEs) for Neuroblastoma, 2002-2003.

NIH Study Section

NIH Center for Scientific Review Special Emphasis Panel, Clinical Oncology, July 2000

Ad Hoc Member, NIH-NCI Cancer Biomarkers Study Section, June 2009

Editorial Boards

Member, Editorial Board, Pediatric Blood and Cancer, August 2009-present.

Journal Reviews

American Journal of Epidemiology,

American Journal of Public Health

Blood

Clinical Cancer Research

Controlled Clinical Trials

Journal of Clinical Oncology

Journal of Pediatric Hematology/Oncology

Journal of Radiation Research

Journal of the National Cancer Institute

Journal of the American Statistical Association

Medical and Pediatric Oncology

Neurooncology

Pediatric Blood and Cancer

Radiation Research
Sankya
Statistics in Medicine

Grant Reviews

United Kingdom Children's Cancer Study Group (UKCCSG) Quinquennial Review Committee, Leicester, UK, June 2003. **(International)**

Cancer Research UK Project Grant Application Review, Population and Behavioural Sciences, September, 2007. **(International)**

National Cancer Institute of Canada special review panel for multidisciplinary program application is entitled "Childhood, Adolescent and Young Adult Cancer Survivors Research Program", November 2007 **(International)**.

Jonsson Comprehensive Cancer Center Ad Hoc External Advisory Committee, January 2007

Other

Sessions Chaired

"Cure Models and Clinical Research", at Eastern North American Region of the Biometrics society (ENAR) meeting, Memphis, Tennessee, 1997: p. March 25.

Consultantships

Expert Advisor, Department of Statistics, Radiation Effects Research Foundation, Hiroshima, Japan, April 1, 2000 – March 31, 2002

F. **Research Activities:**

Complete Bibliography (Attached)

Major Areas of Research Interest

Parametric statistical models of long-term outcome of pediatric cancer.
Statistical issues in early phase trial design in pediatric and adult cancer.
Studies of treatment and biology of pediatric and adult neoplasms.

Research Grants in Past Five Years

USC/Norris Comprehensive Cancer Center Biostatistics Core Resource
P30 CA014089-34 (Susan Groshen) \$1,004,179

NIH/NCI

Co-investigator

12/1/2005-11/30/2010

This is the biostatistics core of the Norris Comprehensive Cancer Center at USC/Keck School of Medicine

Children's Oncology Group Statistics and Data Center

5U10 CA098413-03 (James Anderson)
NIH/NCI
Co-investigator
03/1/2006 – 02/28/2008

The Statistics and Data Center of the COG is a core resource that comprises the Statistics Department of the COG, which provides all statistical science support of group research, and a Data Operations Department, which is responsible for all data acquisition, quality control, quality assurance, and reporting, of COG research data

Human models of sickle cell vascular damage
5R01 HL071801-03 (Thomas Coates)
NIH/NHLBI
Co-investigator
07/01/2005-06/30/2007

This project will test the ability of anti-inflammatory agents to block decrease in blood flow directly measured in the skin, deep tissue and bone marrow of subjects with sickle cell anemia.

Localization and Function of iNKT Cells in Neuroblastoma
1R01CA116548-01 (Leonid Metelitsa) \$228,165
NIH/NCI
Co-investigator
07/01/2005-06/30/2010

Provide the fundamental basis for the development of tumor immunotherapy that would realize the potential of Vct24-invariant natural killer T (iNKT) cells to mediate effective anti-tumor immune responses.

Diagnostic and Prognostic Sarcoma Signatures
1U01CA114757-01 (Timothy Triche) \$1,731,711
NIH/NCI
Co-investigator
09/27/2005 - 05/31/2010

The purpose of this initiative is to build on recent demonstrations that molecular signatures correlate with important clinical parameters in cancer.

Clinical Correlative Studies of Neuroblastoma
5R01 CA060104-17 (Robert Seeger) \$428,770
NIH/NCI
Co-investigator
8/1/1993-7/31/2011

The purpose of this grant is to characterize the biology of Neuroblastoma with the aim toward identifying targetable biological features

Clinical Correlative Studies of Neuroblastoma (ARRA Supplement)
3R01CA060104-16S1 (Robert Seeger) \$397,563
NIH/NCI
8/1/2009 – 7/31/2011
Co-investigator

The purpose of this grant is to characterise the biology of Neuroblastoma with the aim toward identifying targetable biological features. (ARRA Supplement)

The Therapeutically Applicable Research to Generate Effective Treatments (NBL-TARGET) Initiative
U10CA098543 (John Maris/Robert Seeger) \$421,986
NIH/NCI

Co-investigator
3/1/2008-2/28/2009

The purpose of this grant is to use high throughput assay methods (SNP, Expression) to identify potential therapeutic targets for the treatment of neuroblastoma

Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
1R01HL95110-01 (Guy Young) \$212,963
NIH/NHLBI

Co-investigator
9/26/2008 – 7/31/2010

The purpose of this study is to determine whether bivalirudin is a safer and more effective alternative treatment for thrombosis in children with chronic diseases.

hESC as Tools to Investigate the Neural Crest Origin of Ewing's Sarcoma
8018-RCS004326-02 (Elizabeth Lawlor)
CIRM

Co-investigator
8/1/2007 – 7/31/2009

The purpose of this grant is to test whether pathogenesis of NC-derived tumors involves genetic mutations that disrupt embedded NC developmental programs

Iron-Mediated Vascular Disease in Sickle Cell Disease
1RC1HL099412-01 (John Wood) \$495,180
NIH/NHLBI

Co-investigator
9/30/2009-8/31/2011

This study tests the hypothesis that clinically significant iron overload is common in subjects with sickle cell disease (SCD) and exacerbates sickle vasculopathy. The study represents an essential first step in the design of a subsequent clinical trial to improve vascular function in SCD patients

Los Angeles Basin Clinical and Translation Science Institute
1KL2RR031991-01 (Thomas Buchanan) \$805,680
NIH

Co-investigator
7/1/2010-3/31/2015

One of the national CTSI's that have been formed in the last several years.

Prognostication of Medulloblastomas Using Gene Networks
119779 (Shahab Asgharzadeh)
ACS

Co-investigator

1/1/2011 – 12/31/2014

The overall goal of this project is to develop genomic classifiers for children with medulloblastoma that can be implemented for treatment planning.

Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome

R33CA152809-01 (Robert Seeger)

NIH/NCI

Co-investigator

9/1/2010 – 8/21/2013

This project is to develop a RT-PCR based tumor signature to detect minimum residual disease in neuroblastoma

Receptor Re-expression in ER and PR Negative Breast Cancer

16IB-0106 (Dennis Holmes)

CBCRP

Co-investigator

7/1/2010 – 12/31/2011

Clinical research project to assess the effect of reexpression of ER and PR on outcome in receptor negative breast cancer

G. Invited Lectures

Invited Speaker: "Parametric Cure Models in Pediatric Cancer", at Conference on Mathematical Models in Medical and Health Sciences, Vanderbilt University. *May 28-31, 1997.*

Invited Speaker: "A Strategic View of Randomized Trial Design in Low-Incidence Pediatric Cancer", Workshop on "Clinical Trials in Rare Conditions, at Society for Clinical Trials, Atlanta, GA. *May 19, 1998.*

Invited Speaker: "Risk Stratification in Pediatric Cancer", Mini-symposium on "Statistical Challenges in Pediatric Research", at International Society for Clinical Biostatistics, Trento, Italy. *September 8, 2000.*

Invited Speaker: "Clinical Trials Design in Pediatric Oncology" at Workshop on Pediatric Oncology Drug Development, Center for Drug Evaluation and Research, FDA. *July 18, 2002.*

Invited Speaker: "Pediatric Cooperative Group Research in COG", UKCCSG Meeting of International Statisticians, Leicester, UK. *May 29-30, 2003.*

Invited Speaker: "Design of Clinical Trials for Pediatric Cancers", at Statistical Symposium of the Society of Clinical and Biostatistical Research, Chuo University, Tokyo, Japan. *December 16, 2006.*

Invited Speaker: "System and Logistics for Clinical Trials for Pediatric Oncology in the U.S.A.", at Statistical Symposium of the Society of Clinical and Biostatistical Research, Chuo University, Tokyo, Japan. *December 16, 2006.*

Invited speaker: "Design of Phase I and II Trials for New Therapies for Neuroblastoma", workshop on Methods for Clinical Trials at Advances in Neuroblastoma Research Meeting. *May 20, 2006.*

Invited Speaker: "Risk/Benefit Analysis of Targeted Treatment Strategies in Childhood Cancer" at Contemporary Clinical Trials Seminar Series, Department of Biostatistics in the Division of Information Sciences, City of Hope. *July 18, 2007.*

Invited Speaker: "Basic Concepts of Phase II Trial Design", workshop on Clinical Trial Design: The Challenges of Middle Development (Phase II), AACR, *April 17, 2010.*

H. Bibliography

Peer Reviewed.

1. Paulson MJ, Stone D, and **Sposto R**
Suicide potential and behavior in children ages 4 to 12
Suicide & Life-Threatening Behavior, 1978. 8(4): p. 225-42.
2. Jenkin RD, Anderson JR, Chilcote RR, Coccia PF, Exelby PR, Kersey JH, Kushner JH, Meadows AT, Siegel SE, and **Sposto R**
The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group
Journal of Clinical Oncology, 1984. 2(2): p. 88-97.
3. Packer RJ, Sutton LN, Rorke LB, Littman PA, **Sposto R**, Rosenstock JG, Bruce DA, and Schut L
Prognostic importance of cellular differentiation in medulloblastoma of childhood
Journal of Neurosurgery, 1984. 61(2): p. 296-301.
4. Stowe SM, Hammond GD, Chard R, Hornberger JA, Honour RC, **Sposto R**, and Weiner JM
Monitoring clinical research. A report from the Childrens Cancer Study Group
American Journal of Clinical Oncology, 1984. 7(5): p. 557-66.
5. Wilson JF, Jenkin RD, Anderson JR, Chilcote RR, Coccia P, Exelby PR, Kersey J, Kjeldsberg CR, Kushner J, Meadows A, Sheehan WW, Siegel S, **Sposto R**, Leikin S, and Hammond D
Studies on the pathology of non-Hodgkin's lymphoma of childhood. I. The role of routine histopathology as a prognostic factor. A report from the Children's Cancer Study Group
Cancer, 1984. 53(8): p. 1695-704.
6. **Sposto R** and Sather HN
Determining the duration of comparative clinical trials while allowing for cure
Journal of Chronic Diseases, 1985. 38(8): p. 683-90.
7. Jenkin RD, Boesel C, Ertel I, Evans A, Hittle R, Ortega J, **Sposto R**, Wara W, Wilson C, and Anderson J
Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group

- Journal of Neurosurgery, 1987. 66(2): p. 227-33.
8. Packer RJ, Littman PA, **Sposto R**, G DA, Priest JR, Heideman RL, Bruce DA, and Nelson DF
Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas
International Journal of Radiation Oncology, Biology, Physics, 1987. 13(11): p. 1647-51.
 9. Packer RJ, **Sposto R**, Atkins TE, Sutton LN, Bruce DA, Siegel KR, Rorke LB, Littman PA, and Schut L
Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa
Pediatric Neuroscience, 1987. 13(4): p. 169-75.
 10. **Sposto R** and Krailo MD
Use of unequal allocation in survival trials
Statistics in Medicine, 1987. 6(2): p. 119-25.
 11. Wilson JF, Kjeldsberg CR, **Sposto R**, Jenkin RD, Chilcote RR, Coccia P, Exelby RR, Kersey J, Meadows A, and Siegel S
The pathology of non-Hodgkin's lymphoma of childhood: II. Reproducibility and relevance of the histologic classification of "undifferentiated" lymphomas (Burkitt's versus non-Burkitt's)
Human Pathology, 1987. 18(10): p. 1008-14.
 12. Meadows AT, **Sposto R**, Jenkin RD, Kersey JH, Chilcote RR, Siegel SE, Coccia PF, Rosenstock J, Pringle KC, and Stolar CJ
Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group
Journal of Clinical Oncology, 1989. 7(1): p. 92-9.
 13. Nakamura N, **Sposto R**, Miller RC, Hiraoka T, and Takeichi N
X-ray-induced mutations in cultured human thyroid cells
Radiation Research, 1989. 119(1): p. 123-33.
 14. **Sposto R**, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, and Hammond D
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group
Journal of Neuro-Oncology, 1989. 7(2): p. 165-77.
 15. Evans AE, Jenkin RD, **Sposto R**, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, and Leikin SL
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone
Journal of Neurosurgery, 1990. 72(4): p. 572-82.
 16. Nakamura N, **Sposto R**, Kushiro J, and Akiyama M
Is interindividual variation of cellular radiosensitivity real or artifactual?
Radiation Research, 1991. 125(3): p. 326-30.

17. **Sposto R**, Stram DO, and Awa AA
An estimate of the magnitude of random errors in the DS86 dosimetry from data on chromosome aberrations and severe epilation
Radiation Research, 1991. 128(2): p. 157-69.
18. Stram DO and **Sposto R**
Recent uses of biological data for the evaluation of A-bomb radiation dosimetry
Journal of Radiation Research, 1991. 32(Suppl): p. 122-35.
19. Fujiwara S, **Sposto R**, Ezaki H, Akiba S, Neriishi K, Kodama K, Hosoda Y, and Shimaoka K
Hyperparathyroidism among atomic bomb survivors in Hiroshima
Radiation Research, 1992. 130(3): p. 372-8.
20. **Sposto R**, Preston DL, Shimizu Y, and Mabuchi K
The effect of diagnostic misclassification on non-cancer and cancer mortality dose response in A-bomb survivors
Biometrics, 1992. 48(2): p. 605-17.
21. **Sposto R**, Sather HN, and Baker SA
A comparison of tests of the difference in the proportion of patients who are cured
Biometrics, 1992. 48(1): p. 87-99.
22. Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, **Sposto R**, Chilcote RR, Coccia PF, Exelby PR, Siegel S, and Meadows AT
Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group [see comments]
Journal of Clinical Oncology, 1993. 11(6): p. 1024-32.
23. Nakamura N, **Sposto R**, and Akiyama M
Dose survival of G0 lymphocytes irradiated in vitro: a test for a possible population bias in the cohort of atomic bomb survivors exposed to high doses
Radiation Research, 1993. 134(3): p. 316-22.
24. Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, Berman P, Twaddell T, Stablein D, and **Sposto R**
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
Lancet, 1993. 342(8863): p. 69-73.
25. Stram DO, **Sposto R**, Preston D, Abrahamson S, Honda T, and Awa AA
Stable chromosome aberrations among A-bomb survivors: an update
Radiation Research, 1993. 136(1): p. 29-36.
26. Belshe RB, Clements ML, Keefer MC, Graham BS, Corey L, **Sposto R**, Wescott S, and Lawrence D
Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group

- Annals of Internal Medicine, 1994. 121(8): p. 584-9.
27. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, and **Sposto R**
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network [see comments]
Jama, 1994. 272(6): p. 475-80.
 28. Fujiwara S, **Sposto R**, Shiraki M, Yokoyama N, Sasaki H, Kodama K, and Shimaoka K
Levels of parathyroid hormone and calcitonin in serum among atomic bomb survivors
Radiation Research, 1994. 137(1): p. 96-103.
 29. Ohtaki K, **Sposto R**, Kodama Y, Nakano M, and Awa AA
Aneuploidy in somatic cells of in utero exposed A-bomb survivors in Hiroshima
Mutation Research, 1994. 316(1): p. 49-58.
 30. **Sposto R**, Stablein D, and Carter-Campbell S
A partially grouped logrank test
Statistics in Medicine, 1997. 16(6): p. 695-704.
 31. Reaman G, **Sposto R**, Sensel M, Lange B, Feusner J, Heerema N, Leonard M, Holmes E, Sather H, Pendergrass T, Johnstone H, O'Brien R, Steinherz P, Zeltzer P, Gaynon P, Trigg M, and Uckun F
Treatment Outcome and Prognostic Factors for Infants with Acute Lymphoblastic Leukemia Treated on Two Consecutive Trials of the Children's Cancer Group
Journal of Clinical Oncology, 1999. 17(2): p. 445-455.
 32. **Sposto R** and Stram DO
A strategic view of randomized trial design in low-incidence paediatric cancer
Statistics in Medicine, 1999. 18(10): p. 1183-97.
 33. Albright AL, **Sposto R**, Holmes E, Zeltzer PM, Finlay JL, Wisoff JH, Berger MS, Packer RJ, and Pollack IF
Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors
Neurosurgery, 2000. 47(4): p. 879-885.
 34. Davis SE, Levy ML, McComb JG, and **Sposto R**
The delta valve: how does its clinical performance compare with two other pressure differential valves without antisiphon control?
Pediatric Neurosurgery, 2000. 33(2): p. 58-63.
 35. Gururangan S, **Sposto R**, Cairo MS, Meadows AT, and Finlay JL
Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study
Journal of Clinical Oncology, 2000. 18(10): p. 2017-25.

36. Lones MA, Perkins SL, **Sposto R**, Kadin ME, Kjeldsberg CR, Wilson JF, and Cairo MS
Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: A Children's cancer group report
Journal of Clinical Oncology, 2000. 18(22): p. 3845-3853.
37. Syed AM, Puthawala AA, Damore SJ, Cherlow JM, Austin PA, **Sposto R**, and Ramsinghani NS
Brachytherapy for primary and recurrent nasopharyngeal carcinoma: 20 years' experience at Long Beach Memorial
International Journal of Radiation Oncology, Biology, Physics, 2000. 47(5): p. 1311-21.
38. Kobrinsky NL, **Sposto R**, Shah NR, Anderson JR, DeLaat C, Morse M, Warkentin P, Gilchrist GS, Cohen MD, Shina D, and Meadows AT
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912
Journal of Clinical Oncology, 2001. 19(9): p. 2390-6.
39. Markland FS, Shieh K, Zhou Q, Golubkov V, Sherwin R, Richters V, and **Sposto R**
A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model
Haemostasis, 2001. 31(3): p. 183-91.
40. Pollack IF, Finkelstein SD, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Finlay J, and **Sposto R**
Age and TP53 mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort.
Cancer Research, 2001. 61(20): p. 7404-7407.
41. Skinner K, Silberman H, **Sposto R**, and Silverstein M
Palpable Breast Cancers are Inherently Different from Nonpalpable Breast Cancers
Annals of Surgical Oncology, 2001. 8(9): p. 705-710.
42. Skinner KA, Silberman H, Dougherty W, Gamagami P, Waisman J, **Sposto R**, and Silverstein MJ
Breast cancer after augmentation mammoplasty
Annals of Surgical Oncology, 2001. 8(2): p. 138-144.
43. **Sposto R**, Meadows AT, Chilcote RR, Kjeldsberg C, Kadin ME, Krailo MD, Morse M, and Siegel SE
Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin's lymphoma treated with COMP or Daunomycin-COMP : A report from the Children's Cancer Group
Medical and Pediatric Oncology, 2001. 37(5): p. 432-441.
44. Helsper J, Ye W, Deapen D, **Sposto R**, and Skinner K
Breast Cancer: Do Specialists Make a Difference?
Annals of Surgical Oncology, 2002. 10(6): p. 606-615.

45. Jennings MT, **Sposto R**, Boyett JM, Vezina LG, Holmes E, Berger MS, Bruggers CS, Bruner JM, Chan KW, Dusenbery KE, Ettinger LJ, Fitz CR, Lafond D, Mandelbaum DE, Massey V, McGuire W, McNeely L, Moulton T, Pollack IF, and Shen V
Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group
Journal of Clinical Oncology, 2002. 20(16): p. 3431-7.
46. Lones MA, Perkins SL, **Sposto R**, Tedeschi N, Kadin ME, Kjeldsberg CR, Wilson JF, Zwick DL, and Cairo MS
Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report
Journal of Clinical Oncology, 2002. 20(9): p. 2293-301.
47. Nachman J, **Sposto R**, Herzog P, Cich J, Fryer C, Hutchinson R, Kadin ME, and White K
Randomized comparison of low-dose involved field radiation and no radiation for children with Hodgkin's disease who achieve a complete response to chemotherapy.
Journal of Clinical Oncology, 2002. 20(18): p. 3765-3771.
48. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, and **Sposto R**
Expression of p53 and prognosis in children with malignant gliomas
New England Journal of Medicine, 2002. 346(6): p. 420-7.
49. Pollack IF, Hamilton RL, Burnham J, Holmes EJ, Finkelstein SD, **Sposto R**, Yates AJ, Boyett JM, and Finlay JL
The impact of proliferation index on outcome in childhood malignant gliomas: Results in a multi-institutional cohort
Neurosurgery, 2002. 50(6): p. 1238-44.
50. **Sposto R**
Cure model analysis in cancer: An application to data from the Children's Cancer Group.
Statistics in Medicine, 2002. 21: p. 293-312.
51. Woo C, Nakamura S, Silberman H, Ye W, **Sposto R**, Colburn J, Waisman J, and Silverstein M
Lymph Nodes Status Combined with Lymphovascular Invasion: A More Powerful Tool for Predicting Outcome in Patients with Invasive Breast Cancer
American Journal of Surgery, 2002. 184(4): p. 337-40.
52. Cairo MS, **Sposto R**, Hoover-Regan M, Meadows AT, Anderson JR, Siegel SE, Kadin ME, Kjeldsberg CR, Wilson JF, Perkins SL, Lones MA, Morris E, and Finlay JL
Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience
Am J Hematol, 2003. 72(1): p. 53-63.

53. Cairo MS, **Sposto R**, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, Siegel SE, Lones MA, Tedeschi-Blok N, Kadin ME, Kjeldsberg CR, Wilson JF, Sanger W, Morris E, Krailo MD, and Finlay JL
Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience
Br J Haematol, 2003. 120(4): p. 660-70.
54. Sabesan V, Cairo M, Lones M, Perkins S, Morris E, **Sposto R**, Van De Ven C, and Shiramizu B
Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers.
J Pediatr Hematol Oncol, 2003. 25(2): p. 109-13.
55. Skinner KA, Helsper JT, Deapen D, Ye W, and **Sposto R**
Breast cancer: do specialists make a difference?[see comment]
Annals of Surgical Oncology, 2003. 10(6): p. 606-15.
56. Broniscer A, Nicolaidis TP, Dunkel IJ, Gardner SL, Johnson J, Jr., Allen JC, **Sposto R**, and Finlay JL
High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors
Pediatric Blood & Cancer, 2004. 42(3): p. 261-7.
57. Lones MA, Sanger WG, Le Beau MM, Heerema NA, **Sposto R**, Perkins SL, Buckley J, Kadin ME, Kjeldsberg CR, Meadows A, Siegel S, Finlay J, Bergeron S, Cairo MS, and Children's Cancer Group Study C-E
Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08
Journal of Pediatric Hematology/Oncology, 2004. 26(3): p. 169-78.
58. Geyer JR, **Sposto R**, Jennings M, Boyett JM, Axtell RA, Breiger D, Broxson E, Donahue B, Finlay JL, Goldwein JW, Heier LA, Johnson D, Mazewski C, Miller DC, Packer R, Puccetti D, Radcliffe J, Tao ML, Shiminski-Maher T, and Children's Cancer G
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group
Journal of Clinical Oncology, 2005. 23(30): p. 7621-31.
59. Hiotis K, Ye W, **Sposto R**, Goldberg J, Mukhi V, and Skinner K
The importance of location in determining breast conservation rates
American Journal of Surgery, 2005. 190(1): p. 18-22.
60. Hiotis K, Ye W, **Sposto R**, and Skinner KA
Predictors of breast conservation therapy
Cancer, 2005. 103(5): p. 892-9.

61. MacDonald TJ, Arenson EB, Ater J, **Sposto R**, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O'Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, and Packer R
Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933
Cancer, 2005. 104(12): p. 2862-71.
62. Asgharzadeh S, Pique-Regi R, **Sposto R**, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, and Seeger RC
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification
Journal of the National Cancer Institute, 2006. 98(17): p. 1193-203.
63. Lones MA, Heerema NA, Le Beau MM, Perkins SL, Kadin ME, Kjeldsberg CR, **Sposto R**, Meadows A, Siegel S, Buckley J, Finlay J, Abromowitch M, Cairo MS, and Sanger WG
Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08
Cancer Genet Cytogenet, 2006. 171(2): p. 89-96.
64. Lones MA, Raphael M, Auperin A, Perkins SL, Wotherspoon A, Terrier-Lacombe M-J, **Sposto R**, Weston C, Gerrard M, Patte C, Cairo MS, and McCarthy K
Mature B-cell Lymphoma in Children and Adolescents: International Group Pathologist Consensus Correlates with Histology Technical Quality
Journal of Pediatric Hematology/Oncology, 2006. 28(9): p. 568-574.
65. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, and **Sposto R**
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma
Journal of Clinical Oncology, 2006. 24(25): p. 4202-8.
66. Robertson PL, Muraszko KM, Holmes EJ, **Sposto R**, Packer RJ, Gajjar A, Dias M, and Allen JC
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: A prospective study by the Children's Oncology Group
Journal of Neurosurgery (6 Suppl Pediatrics), 2006. 105: p. 444-451.
67. Cairo MS, Gerrard M, **Sposto R**, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, and Patte C
Results of a randomized international study of high risk central nervous system B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukemia in children and adolescents
Blood, 2007. 109(7): p. 2736-2743.
68. Flores-Delgado G, Liu CWY, **Sposto R**, and Berndt N
A limited screen for protein interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis
Journal of Proteome Research, 2007. 6(3): p. 1165-1175.

69. Keshelava N, Davicioni E, Wan Z, Ji L, **Sposto R**, Triche TJ, and Reynolds CP
Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide
J. Natl. Cancer Inst., 2007: p. djm044.
70. Lones MA, Heerema NA, Le Beau MM, **Sposto R**, Perkins SL, Kadin ME, Kjeldsberg CR, Meadows A, Siegel S, Buckley J, Abromowitch M, Kersey J, Bergeron S, Cairo MS, and Sanger WG
Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08
Cancer Genet Cytogenet, 2007. 172(1): p. 1-11.
71. Miles RR, Cairo MS, Satwani P, Zwick DL, Lones MA, **Sposto R**, Abromovitch M, Tripp S, Angiolillo AL, Roman E, Davenport V, and Perkins SL
Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report
British Journal of Haematology, 2007. 138(4): p. 506-512.
72. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, **Sposto R**, Weston C, Raphael M, Perkins SL, McCarthy K, and Cairo MS
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin's lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
Blood, 2007. 109(7): p. 2773-2780.
73. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, **Sposto R**, and Metelitsa LS
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma
Journal of Clinical Investigation, 2007. 117(9): p. 2702-2712.
74. **Sposto R**, London WB, and Alonzo TA
Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group
Journal of Clinical Oncology, 2007. 25(15): p. 2070-7.
75. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, **Sposto R**, Chauvenet A, and Schwartz CL
Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Journal of Clinical Oncology, 2007. 25(5): p. 493-500.
76. Teot L, **Sposto R**, Khayat A, Qualman S, Reaman G, and Parham D
The Problems and Promise of Central Pathology Review: Development of a Standardized Procedure for the Children's Oncology Group
Pediatr Dev Pathol, 2007: p. 1.

77. Zacharoulis S, Levy A, Chi S, Gardner S, Rosenblum M, Miller D, Dunkel I, Diez B, **Sposto R**, Ji L, Asgharzadeh S, Hukin J, Belasco J, Dubowy R, Kellie S, Termuhlen A, and Finlay J
Outcome for young children with newly diagnosed ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue
Pediatric Blood & Cancer, 2007. 49(1): p. 34-40.
78. Abromowitch M, **Sposto R**, Perkins S, Zwick D, Siegel S, Finlay J, and Cairo MS
Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group
British Journal of Haematology, 2008. 143(2): p. 261-267.
79. Armenian SH, Sun C-L, Francisco L, Steinberger J, Kurian S, Wong FL, Sharp J, **Sposto R**, Forman SJ, and Bhatia S
Late Congestive Heart Failure (CHF) Following Hematopoietic Cell Transplantation (HCT)
Journal of Clinical Oncology, 2008. 26(34): p. 5537-5543.
80. Dhall G, Grodman H, Ji LY, Sands S, Gardner S, Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS, Termuhlen A, Abromowitch M, **Sposto R**, and Finlay JL
Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols
Pediatric Blood & Cancer, 2008. 50(6): p. 1169-1175.
81. Fangusaro J, Finlay J, **Sposto R**, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller DC, Allen J, and Gardner S
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumor (sPNETs): Report of the head start I and II experience
Pediatric Blood & Cancer, 2008. 50(2): p. 312-318.
82. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliotte A, **Sposto R**, McCarthy K, Lacombe M-JT, Perkins SL, Patte C, and Committee FLIS
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
British Journal of Haematology, 2008. 141(6): p. 840-7.
83. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, **Sposto R**, Neuwelt EA, and Reynolds CP
Sodium Thiosulfate (STS) Administered Six Hours After Cisplatin Does Not Compromise Anti-Neuroblastoma Activity
Clinical Cancer Research, 2008. 14: p. 533-540.

84. Kang MH, Wan Z, Kang YH, **Sposto R**, and Reynolds CP
Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation
Journal of the National Cancer Institute, 2008. 100(8): p. 580-595.
85. Kim A, Ji L, Balmaceda C, Diez B, Kellie S, Dunkel IJ, Gardner SL, **Sposto R**, and Finlay JL
The Prognostic Value of Tumor Markers in Newly Diagnosed Patients with Primary Central Nervous System Germ Cell Tumors
Journal of Pediatric Hematology/Oncology, 2008. 51: p. 768-773.
86. Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Patte C, Gerrard M, Auperin A, **Sposto R**, Davenport V, Cairo MS, Perkins SL, and Group SLCUNS
Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group
Pediatric Blood & Cancer, 2008. 51(3): p. 369-74.
87. Panigrahy A, Finlay JL, Jr MDN, Krieger MD, **Sposto R**, Gilles FH, and Blüml S
Metabolism of diffuse intrinsic brain stem gliomas in children
Neurooncology, 2008. 10(1): p. 32-44.
88. Zacharoulis S, Ji L, Pollack IF, Duffner PK, Geyer JR, Grill J, Schild SE, Jaing TH, Massimino M, Finlay JL, and **Sposto R**
Metastatic ependymoma: A multi-institutional retrospective analysis of prognostic factors
Pediatr Blood Cancer, 2008. 50(2): p. 231-5.
89. Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, **Sposto R**, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, and Chan KW
A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931)
International Journal of Radiation Oncology, Biology, Physics, 2009. 74(4): p. 1006-11.
90. Lowe EJ, **Sposto R**, Perkins SL, Gross TG, Finlay J, Zwick D, Abromowitch M, and Children's Cancer Group S
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941
Pediatric Blood & Cancer, 2009. 52(3): p. 335-9.
91. Meeske KA, Siegel SE, Gilsanz V, Bernstein L, Nelson MB, **Sposto R**, Weaver FA, Lavey RS, Mack MP, and Nelson MD, Jr.
Premature carotid artery disease in pediatric cancer survivors treated with neck irradiation
Pediatric Blood Cancer, 2009. 53(4): p. 615-21.

92. Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley P, Perkins SL, Raphael M, McCarthy K, **Sposto R**, Gerrard M, Bernheim A, and Patte C
Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
Leukemia, 2009. 23(2): p. 323-31.
93. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, **Sposto R**, Lipshultz SE, Turner CS, Dealarcon PA, and Chauvenet A
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high risk Hodgkin lymphoma: the results of P9425 from the Children's Oncology Group
Blood, 2009. 114(10): p. 2051-2059.
94. Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, **Sposto R**, Ara T, Silverman AM, DeClerck YA, Seeger RC, and Metelitsa LS
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
Journal of Clinical Investigation, 2009. 119(6): p. 1524-36.
95. **Sposto R** and Gaynon PS
An adjustment for patient heterogeneity in the design of two-stage phase II trials
Statistics in Medicine, 2009. 28(20): p. 2566 - 2579.
96. Cai W, Maldonado NV, Cui W, Harutyunyan N, Ji L, **Sposto R**, Reynolds CP, and Keshelava N
Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
Br J Cancer, 2010. 103(9): p. 1369-79.
97. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, **Sposto R**, Gaynon PS, and Loh ML
Outcome for Children Treated for Relapsed or Refractory Acute Myelogenous Leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Study
Pediatr Blood Cancer, 2010. 55(3): p. 421-429.
98. Gruber TA, Chang MS, **Sposto R**, and Mischen M
Activation-induced cytidine deaminase accelerates clonal evolution of BCR-ABL1-driven B cell lineage acute lymphoblastic leukemia
Cancer Research, 2010. 70(19): p. 7411-7420.
99. Huang JM, Sheard MA, Ji LY, **Sposto R**, and Keshelava N
Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53
Molecular Cancer Therapeutics, 2010. 9(12): p. 3289-3301.

100. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, **Sposto R**, and Finlay JL
Treatment of Primary CNS Germinomatous Germ Cell Tumors With Chemotherapy Prior to Reduced Dose Whole Ventricular and Local Boost Irradiation
Pediatric Blood & Cancer, 2010. 55(1): p. 42-46.
101. Ko RH, Ji LY, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, **Sposto R**, Gaynon PS, and Loh ML
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Journal of Clinical Oncology, 2010. 28(4): p. 648-654.
102. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, **Sposto R**, van der Giessen J, Eckroth E, and Bostrom BC
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium
Pediatr Blood Cancer, 2010. 55(2): p. 254-259.
103. Serowka K, Chiu Y, Gonzalez I, Gilles F, McComb G, Krieger M, Dhall G, Britt B, Ji L, **Sposto R**, and Finlay JL
Central Nervous System (Cns) Tumors in the First Six Months of Life: The Childrens Hospital Los Angeles Experience, 1979-2005
Pediatric Hematology and Oncology, 2010. 27(2): p. 90-102.
104. Song HR, Gonzalez-Gomez I, Suh GS, Commins DL, **Sposto R**, Gilles FH, Deneen B, and Erdreich-Epstein A
Nuclear factor IA is expressed in astrocytomas and is associated with improved survival
Neuro-Oncology, 2010. 12(2): p. 122-132.
105. van Doorninck JA, Ji LY, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, **Sposto R**, Womer RB, and Lawlor ER
Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group
Journal of Clinical Oncology, 2010. 28(12): p. 1989-1994.
106. Wells EM, Khademian ZP, Walsh KS, Vezina G, **Sposto R**, Keating RF, and Packer RJ
Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin
Clinical article
Journal of Neurosurgery-Pediatrics, 2010. 5(4): p. 329-334.
107. Cooper A, van Doorninck J, Ji LY, Russell D, Ladanyi M, Shimada H, Krailo M, Womer RB, Hsu JHR, Thomas D, Triche TJ, **Sposto R**, and Lawlor ER
Ewing Tumors That Do Not Overexpress BMI-1 Are a Distinct Molecular Subclass with Variant Biology: A Report from the Children's Oncology Group
Clinical Cancer Research, 2011. 17(1): p. 56-66.

108. Kelly KM, **Sposto R**, Hutchinson R, Massey V, McCarten K, Perkins S, Lones M, Villaluna D, and Weiner M
BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group
Blood, 2011. 117(9): p. 2596-2603.
109. O'Neil S, Ji L, Buranahirun C, Azoff J, Dhall G, Khatua S, Patel S, Panigrahy A, Borchert M, **Sposto R**, and Finlay J
Neurocognitive outcomes in pediatric and adolescent patients with central nervous system germinoma treated with a strategy of chemotherapy followed by reduced-dose and volume irradiation
Pediatric Blood Cancer, 2011. 57(4): p. 669-673.
110. Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, **Sposto R**, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, and Matthay KK
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma
Pediatr Blood Cancer, 2011. 56(2): p. 191-201.
111. **Sposto R** and Groshen S
A wide-spectrum paired comparison of the properties of the Rolling 6 and 3 + 3 Phase I study designs
Contemporary Clinical Trials, 2011. 32(5): p. 694-703.
112. Wisoff JH, Sanford RA, Heier LA, **Sposto R**, Burger PC, Yates AJ, Holmes EJ, and Kun LE
Primary Neurosurgery for Pediatric Low-Grade Gliomas: A Prospective Multi-Institutional Study From the Children's Oncology Group
Neurosurgery, 2011. 68(6): p. 1548-1554.
113. Lones MA, Raphael M, McCarthy K, Wotherspoon A, Terrier-Lacombe MJ, Ramsay AD, Maclennan K, Cairo MS, Gerrard M, Michon J, Patte C, Pinkerton R, Sender L, Auperin A, **Sposto R**, Weston C, Heerema NA, Sanger WG, von Allmen D, and Perkins SL
Primary follicular lymphoma of the testis in children and adolescents
J Pediatr Hematol Oncol, 2012. 34(1): p. 68-71.

Peer Reviewed in Press.

114. Cairo MS, **Sposto R**, Gerrard M, Waxman I, Goldman S, Harrison L, Auperin A, Pinkerton CR, Raphael M, McCarthy K, Perkins SL, and Patte C
Advanced stage, elevated LDH and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of failure in children and adolescents with mature B-NHL: results of the FAB/LMB 96 study
Journal of Clinical Oncology, 2011. In press.
115. Ruccione KS, Mudambi K, **Sposto R**, Friley J, Ghazarossian S, and Freyer DR
Association of Projected Transfusional Iron Burden with Treatment Intensity in Childhood Cancer Survivors
Pediatr Blood Cancer, 2011. In press.

116. Valente SA, Levine GM, Silverstein MJ, Rayhanabad JA, Weng-Grumley JG, Ji L, Holmes DR, **Sposto R**, and Sener SF
Accuracy of Predicting Axillary Lymph Node Positivity Using Physical Exam, Mammography, Ultrasonography and Magnetic Resonance Imaging
Annals of Surgical Oncology, 2011. In press.
117. Venkatramani R, Wang L, Malvar J, Dias D, **Sposto R**, Malogolowkin MH, and Mascarenhas L
Tumor Necrosis Predicts Survival Following Neo-adjuvant Chemotherapy for Hepatoblastoma
Pediatr Blood Cancer, 2011. In press.
118. Silverman AM, Nakata R, Shimada H, **Sposto R**, and DeClerck YA
A GALECTIN-3-DEPENDENT PATHWAY UPREGULATES INTERLEUKIN-6 IN THE MICROENVIRONMENT OF HUMAN NEUROBLASTOMA
Cancer Research, 2012. In Press.

Non-Peer Reviewed.

1. Sather H, Honour R, **Sposto R**, Level C, and Hammond D
Differences in the presentation of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in black children and white children. In: Pathogenesis of Leukemias and Lymphomas: Environmental Influences.
in Pathogenesis of Leukemias and Lymphomas: Environmental Influences, I. Magrath, G. O'Connor, and B. Ramot, Editors. 1984, Raven Press: New York.
2. **Sposto R** and Hammond D
Survival in Children's Cancer
Clinics in Oncology, 1985. 4: p. 195-204.
3. Allen JC, Bloom J, Ertel I, Evans A, Hammond D, Jones H, Levin V, Jenkin D, **Sposto R**, and Wara W
Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease
Seminars in Oncology, 1986. 13(1): p. 110-22.
4. Preston R and **Sposto R**
RBE and dose-response functions. Is it necessary to introduce the concept of relative biological effectiveness?
RERF Update, 1991. August.
5. Packer RJ, **Sposto R**, Friedman H, and Perilongo G
Cooperative Group Trials
in Tumors of the Pediatric Central Nervous System, R.F. Keating, J.T. Goodrich, and R.J. Packer, Editors. 2001, Thieme: New York.
6. **Sposto R**, Epstein MS, and Silverstein MJ
Predicting Local Recurrence in Patients with Ductal Carcinoma In Situ

- in Ductal Carcinoma In Situ of the Breast, M.J. Silverstein, Editor. 2002, Lippincott, Williams, and Wilkins: New York.
7. **Sposto R**
Design and Role of Clinical Trials
in Paediatric Oncology - 3rd Edition, C.R. Pinkerton, P.N. Plowman, and P. R., Editors.
2004, Arnold: London.
 8. **Sposto R**
Clinical Trials Methodology
in Brain and Spinal Tumors of Childhood, Walker, et al., Editors. 2004, Arnold: New York.
 9. Schwartz CL, Constine LS, London WB, **Sposto R**, Friedman DL, Tebbi CK, Mendenhall N, Chen AR, De Alarcon PA, Villaluna D, and Chauvenet AR
Targeted therapies: Cui prodest?
in Journal of Clinical Oncology. 2007. p. 4691-4692.
 10. Horton TM, **Sposto R**, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, and Whitlock JA
Toxicity Assessment of Molecularly Targeted Drugs Incorporated into Multiagent Chemotherapy Regimens for Pediatric Acute Lymphocytic Leukemia (ALL): Review From an International Consensus Conference
Pediatric Blood & Cancer, 2010. 54(7): p. 872-878.
 11. **Sposto R**
Commentary on paper, 'cancer survival analysis'
Surgical Oncology, 2010. 19(2): p. 59-60; discussion 61.

Peer Reviewed Submitted.

1. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu W-Y, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthey KK, Shimada H, London WB, **Sposto R**, and Seeger RC
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Journal of Clinical Oncology, 2011. Submitted.
2. Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, **Sposto R**, Vezina G, Wisoff JH, Yates A, and Pollack IF
Randomized Study of Two Chemotherapy Regimens for Treatment of Low Grade Glioma in Young Children: A Report from the Children's Oncology Group
Journal of Clinical Oncology, 2011. Submitted.

3. Garvin JH, Selch MT, Holmes E, Berger MS, Biegel J, Cich J, Finlay JL, **Sposto R**, Flannery A, Goldwein JW, Packer RJ, Rorke L, Shiminski-Maher T, Stanley P, Stevens K, Tannous R, and Triche TJ
Phase II Study Of Pre-Irradiation Chemotherapy For Childhood Intracranial Ependymoma. Children's Cancer Group Protocol 9942: A Report From the Children's Oncology Group
Journal of Clinical Oncology, 2011. Submitted.
4. Wolden SL, Chen L, Kelly KM, Herzog P, Thomson JW, **Sposto R**, Kadin ME, and Nachman JB
Long-Term Results of CCG 5942: A Randomized Comparison of Chemotherapy with and without Radiotherapy for Children with Hodgkin Lymphoma: A Report from the Children's Oncology Group
Journal of Clinical Oncology, 2011. Submitted.
5. Xu Y, Sun J, Sheard MA, Tran H, Wan Z, Liu CWY, Asgharzadeh S, **Sposto R**, Wu H-W, and Seeger RC
Suppression of Human Natural Killer Cell Functions by Neuroblastoma Microenvironment-Associated IL-6 and TGF β 1 Is Prevented by Lenalidomide
Journal of Experimental Medicine, 2011. Submitted.
6. Liu Y, Wu H-W, Sheard MA, **Sposto R**, Somanchi SS, Cooper LJJ, Lee DA, and Seeger RC
Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy
Clinical Cancer Research, 2012. Submitted.
7. Messinger YH, Gaynon PS, **Sposto R**, Giessen Jvd, Eckroth E, Malvar J, and Bostrom BC
Bortezomib with Chemotherapy is Highly Active in Advanced B-precursor Acute Lymphoblastic Leukemia. Therapeutic Advances in Childhood Leukemia Lymphoma (TACL) Study.
Blood, 2012. Submitted.
8. Venkatramani R, Kamath S, Wong K, Olch AJ, Malvar J, **Sposto R**, Goodarzian F, Freyer DR, Keens T, and Mascarenhas L
CORRELATION OF CLINICAL AND DOSIMETRIC FACTORS WITH ADVERSE PULMONARY OUTCOMES IN CHILDREN FOLLOWING LUNG IRRADIATION
Cancer, 2012. Submitted.

Abstracts.

1. Evans A, **Sposto R**, Chung C, Ertel I, Jenkin D, Kramer S, Ortega J, and Wilson C
Adjuvant Chemotherapy for Medulloblastoma, Ccsg 942, Rtog 75-02
European Journal of Cancer & Clinical Oncology, 1982. 18(10): p. 1051-1051.
2. Allen J, Ertel I, Evans A, Hammond D, Jenkin D, and **Sposto R**
The Value of Adjuvant Chemotherapy (Prednisone, Ccnu and Vincristine) in the Management of Newly Diagnosed Medulloblastoma, Malignant Astrocytoma and Brain-Stem Glioma - Results from the Childrens Cancer Study-Group (Ccg)

- Canadian Journal of Neurological Sciences, 1984. 11(2): p. 324-324.
3. Allen J, Ertel I, Evans A, Jenkin D, **Sposto R**, and Hammond D
Results of Randomized Chemotherapy Trials for Newly Diagnosed Medulloblastoma, Malignant Astrocytoma, and Brain-Stem Glioma from the Childrens Cancer Study-Group
Annals of Neurology, 1984. 16(3): p. 403-403.
 4. **Sposto R** and Sather HN
Estimating the Length of 2-Armed Randomized Survival Trials Using a Survival Density That Allows for Cure
Controlled Clinical Trials, 1984. 5(3): p. 303-303.
 5. Wilson JF, Kjeldsberg CR, **Sposto R**, Jenkin RDT, and Hammond GD
In Childhood Non-Hodgkins Lymphoma, Classification of the Undifferentiated Lymphomas into Burkitts and Nonburkitts Is Poorly Reproducible and Clinically Irrelevant
Laboratory Investigation, 1984. 50(1): p. A66-A67.
 6. Packer RJ, Bruce DA, Atkins TA, **Sposto R**, Siegel KR, Sutton LN, and Schut L
Factors Impacting on Neurocognitive Outcome in Long-Term Survivors of Primitive Neuroectodermal Tumors Medulloblastoma (Pnet-Mb)
Annals of Neurology, 1986. 20(3): p. 396-397.
 7. Wilson JF, Kjeldsberg CR, and **Sposto R**
Accuracy and Relevance of Histologic Classification of Burkitts Vs Non-Burkitts Lymphoma
Journal of Pathology, 1986. 149(3): p. A245-A246.
 8. Bleyer WA, **Sposto R**, Siegel SE, Meadows AT, Kersey JH, Steinherz PG, Chilcote RR, Jenkin RDT, and Hammond GD
Childhood Non-Hodgkins-Lymphoma and Lymphoma-Leukemia - Concepts of Therapy from Childrens Cancer Study-Group (CcsG) Studies
Journal of Cellular Biochemistry, 1987: p. 188-188.
 9. Finlay J, **Sposto R**, Bertolone S, Cohen H, Geyer R, Turski P, Yates A, Tefft M, Wisoff J, Allen J, and Hammond D
Multicenter Randomized Therapeutic Trial for Children with Newly-Diagnosed High-Grade Astrocytoma - Preliminary-Report of the Childrens-Cancer-Study-Group (CcsG) Study, Ccg-945
Medical and Pediatric Oncology, 1987. 15(6): p. 326-327.
 10. Zeltzer P, Cohen H, Albright L, Allen J, Epstein F, Finlay J, Milstein J, MCGowan D, Mcguire P, Rorke L, **Sposto R**, and Hammond D
Irradiation (Xrt) and 8 Drug in One Day Chemotherapy (8 in 1) (Regimen-B) or Vincristine (Vcr, Ccnu, Prednisone (Pdn) (Regimen-a) for High-Risk Intracranial Primitive Neuroectodermal Tumors of Childhood (Pnet) - Preliminary-Results from the Childrens-Cancer-Study-Group (CcsG)N
Medical and Pediatric Oncology, 1987. 15(6): p. 319-319.

11. Fujiwara S, Shiraki M, **Sposto R**, Kodama K, Sasaki H, Hosoda Y, and Shimaoka K
Parathyroid-Hormone, Calcitonin, and Osteocalcin Levels among Japanese - Population Based Study
Journal of Bone and Mineral Research, 1992. 7: p. S243-S243.
12. Schwartz D, Clements ML, Hopkins J, Berman P, Duliege AM, Twadell T, Ammann A, Belshe R, Gorse G, Matthews T, Bolognesi D, Fast P, **Sposto R**, and Stablein D
Safety and Immunogenicity of Genentech-liib Rgp 120/Hiv-1
Aids Research and Human Retroviruses, 1993. 9: p. S112-S112.
13. Belshe RB, Clements ML, Keefer MC, Graham BS, Corey L, **Sposto R**, Wescott S, Lawrence D, Gorse GJ, Kennedy D, Frey S, Lambert J, Schwartz D, Dolin R, Roberts N, Mcelrath J, Coombs J, Wright P, Karzon D, Fast P, Walker MC, Mestecky J, Jackson S, Stablein D, and Wolff M
Interpreting Hiv Serodiagnostic Test-Results in the 1990s - Social Risks of Hiv Vaccine Studies in Uninfected Volunteers
Annals of Internal Medicine, 1994. 121(8): p. 584-&.
14. Corey L, Mcelrath MJ, Keefer M, Dolin R, Chernoff D, Greenberg PD, Coombs R, Steimer K, and **Sposto R**
An Aveg Phase-I Randomized, Blinded, Controlled Trial in Asymptomatic Hiv-Infected Subjects Using Env-2-3 in Mf-59 with or without Mtp-Pe
Aids Research and Human Retroviruses, 1994. 10: p. S157-S157.
15. Graham BS, Keefer M, Mcelrath MJ, Schwartz D, Gorse G, Matthews T, **Sposto R**, and Chernoff D
Cross-Reactive Neutralizing (Nt) Antibody (Ab) Induced by Native Hiv-1(Sf-2) Rgp120
Aids Research and Human Retroviruses, 1994. 10: p. S155-S155.
16. Keefer MC, Belshe R, Graham B, Mcelrath J, Clements ML, **Sposto R**, and Fast P
Safety Profile of Hiv Vaccination - First 1000 Volunteers of Aids Vaccine Evaluation Group
Aids Research and Human Retroviruses, 1994. 10: p. S139-S140.
17. Mcelrath MJ, Corey L, Clements ML, Belshe R, Keefer M, Graham B, **Sposto R**, and Fast P
Expanded Safety and Immunogenicity Trial of Recombinant Gp120 Vaccines Volunteers (Aveg Protocol-201)
Aids Research and Human Retroviruses, 1994. 10: p. S155-S155.
18. Packer RJ, **Sposto R**, Finlay J, and Boyett J
Survival of Children with High-Grade Gliomas - a Comparison to 2 Sequential Randomized Children Cancer Group Trials
Annals of Neurology, 1995. 38(2): p. 343-343.
19. Packer RJ, Allen JC, Geyer R, Jakacki R, Nicholson HS, Boyett J, and **Sposto R**
Childhood primitive neuroectodermal tumors medulloblastoma: Treatment directions of the Children's Cancer Group
Annals of Neurology, 1997. 42(3): p. P132-P132.

20. Allen J, Prados M, Donahue B, Mehta M, Robertson P, Jakacki R, and **Sposto R**
Preradiotherapy chemotherapy and hyperfractionated craniospinal radiotherapy for high-risk primitive neuroectodermal tumors: A preliminary report of CCG protocol 9931
Annals of Neurology, 1999. 46(3): p. 526-527.
21. Lones MA, Perkins SL, **Sposto R**, Kadin ME, Kjeldsberg CR, and Cairo MS
Large cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: A children's cancer group report.
Blood, 1999. 94(10): p. 522a-522a.
22. Reaman GH, **Sposto R**, Sensel MG, Lange BJ, Feusner JH, Heerema NA, Leonard M, Holmes EJ, Sather HN, Pendergrass TW, Johnstone HS, O'Brien RT, Steinherz PG, Zeltzer PM, Gaynon PS, Trigg ME, and Uckun FM
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group
Journal of Clinical Oncology, 1999. 17(2): p. 445-455.
23. Lones MA, Perkins SL, **Sposto R**, Tedeschi N, Kadin ME, Kjeldsberg CR, Wilson JF, Zwick DR, and Cairo MS
Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: A Children's Cancer Group Report.
Blood, 2000. 96(11): p. 729a-729a.
24. Skinner KA, **Sposto R**, Helsper JT, Baril N, Silberman H, Waisman J, and Silverstein MJ
Risk of invasive local recurrence following therapy for ductal carcinoma in situ is a function primarily of time.
Breast Cancer Research and Treatment, 2001. 69(3): p. 211-211.
25. Heerema NA, Sanger WG, Perkins S, **Sposto R**, Davenport V, Goldman SC, and Cairo MS
High frequency of CMYC rearrangements, 1q21-1q23 duplications and complex karyotypes in B-cell non-Hodgkin lymphoma (NHL) of children and adolescents: A report from Children's Cancer Group (CCG) study CCG-5961.
Blood, 2002. 100(11): p. 566a-566a.
26. Helsper JT, **Sposto R**, Ye W, Deapen D, and Skinner K
Breast cancer: do specialists make a difference?
International Journal of Cancer, 2002: p. 106-106.
27. Helsper JT, Ye W, **Sposto R**, and Skinner KA
Breast cancer: Do specialists make a difference?
Annals of Surgical Oncology, 2002. 9(1): p. S8-S8.
28. Kelly KM, Hutchinson RJ, **Sposto R**, Weiner M, Lones M, Perkins SL, Massey V, Cohen R, and Grp CO
BEACOPP chemotherapy is an active and feasible regimen in children and adolescents with advanced stage Hodgkin's disease: Preliminary results from Children's Cancer Group study CCG-59704.
Blood, 2002. 100(11): p. 776a-776a.

29. Nakamura SK, Woo C, **Sposto R**, Waisman JR, and Silverstein MJ
Ductal carcinoma in situ (DCIS) of the breast: Margin width - The key predictor of local recurrence
Annals of Surgical Oncology, 2002. 9(1): p. S28-S28.
30. Packer RJ, Tarbell N, Jakacki R, Nicholson S, Moghrabi A, **Sposto R**, and Pollack I
Medulloblastoma: Therapeutic progress and treatment strategies of the Children's Oncology Group in 2002
Annals of Neurology, 2002. 52(3): p. S160-S161.
31. Woo CS, Nakamura SK, Ye W, **Sposto R**, and Silverstein MJ
Lymphovascular invasion (LVI): An independent predictor of outcome for patients with invasive breast cancer
Annals of Surgical Oncology, 2002. 9(1): p. S55-S55.
32. Cairo MS, Gerrard M, **Sposto R**, Auperin A, Pinkerton R, Michon J, Perkins S, Raphael M, McCarthy K, Weston C, and Patte C
Poor response to initial reduction therapy (COP) and combined bone marrow and CNS disease are poor prognostic factors in children with advanced (BM +/- CNS) B-NHL treated on the international study FAB/LMB96.
Blood, 2003. 102(11): p. 143a-143a.
33. Garvin J, **Sposto R**, Stanley P, Rorke L, and Packer RJ
Childhood ependymomas: Possible improved survival with the use of preirradiation chemotherapy followed by radiotherapy
Annals of Neurology, 2003. 54: p. S109-S109.
34. Heerema N, Poirel H, Swansbury J, Sanger W, Bernheim A, Talley P, Patte C, Gerrard M, Perkins S, Raphael M, McCarthy K, **Sposto R**, Weston C, and Cairo M
Chromosomal abnormalities of pediatric (ped) and adult diffuse large B-cell lymphoma (DLBCL) differ and may reflect potential differences in oncogenesis. An international pediatric mature B-cell non-Hodgkin lymphoma study (FAB/LMB96).
Blood, 2003. 102(11): p. 845a-845a.
35. Hiotis KL, Ye W, **Sposto R**, and Skinner KA
The demographics of breast cancer survival; is it sociology or biology?
Breast Cancer Research and Treatment, 2003. 82: p. S149-S149.
36. MacDonald TJ, Arenson A, **Sposto R**, Yates A, Phillips P, Deutsch M, Vezina LG, and Packer RJ
High-dose preirradiation chemotherapy for children with newly diagnosed high-grade astrocytomas
Annals of Neurology, 2003. 54: p. S152-S152.
37. Patte C, Gerrard M, Auperin A, Michon J, Pinkerton R, **Sposto R**, Weston C, Raphael M, Perkins S, McCarthy K, and Cairo MS
Early treatment intensity has a major prognostic impact in the "intermediate risk" childhood and adolescent B-cell lymphoma: Results of the international FAB LMB 96 trial.
Blood, 2003. 102(11): p. 143a-143a.

38. Perkins SL, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, Auperin A, Gerrard M, Patte C, Cairo MS, and **Sposto R**
Pediatric mature B-cell lymphoma: Distribution of lymphoma subtype varies between national groups. Results from the FAB/LMB96 international cooperative group study. *Blood*, 2003. 102(11): p. 393a-394a.
39. Sanger W, Swansbury J, Poirel H, Heerema N, Talley P, Bernheim A, **Sposto R**, Cairo MS, Patte C, Ullrich F, Weston C, Lones M, Raphael M, Wotherspoon A, and Gerrard M
Primary (8q24) and secondary chromosome abnormalities (1q, 6q, 13q, & 17p) are similar in pediatric Burkitt lymphoma/Burkitt leukemia & Burkitt-Like lymphoma: A report of the international pediatric B-cell non-hodgkin lymphoma study (FAB/LMB 96). *Blood*, 2003. 102(11): p. 373a-373a.
40. Batra V, **Sposto R**, Geyer JR, Allen J, Pollack I, and Finlay J
Long-term outcome for children less than six years of age with diagnosis of consensus reviewed high-grade gliomas: A report of the CCG-945 study
Neuro-Oncology, 2004. 6(4): p. 450-450.
41. Bouffet E, **Sposto R**, Allen J, Yates A, Pollack I, and Finlay JL
Outcome for children with concensus reviewed pathology of high-grade gliomaof the spinal cord; A report on the CCG-945 study
Neuro-Oncology, 2004. 6(4): p. 450-450.
42. Finlay J, Barra V, Geyer JR, **Sposto R**, and Pollack I
Long-term outcome for children less than six years old with concensus reviewed highgrade gliomas: A report of the childrens oncology group, CCG-945 study
Neuro-Oncology, 2004. 6(4): p. 386-386.
43. Gajjar A, Vezina G, Langston J, Muraszko K, Dias X, Kessels S, **Sposto R**, and Packer R
Results of central imaging review for patients enrolled on average risk medulloblastoma (MB) protocol A9961
Neuro-Oncology, 2004. 6(4): p. 431-431.
44. Garvin J, **Sposto R**, Stanley P, Rorke L, and Packer R
Childhood ependymoma: Improved survival for patients with incompletely resected tumors with the use of preirradiation chemotherapy
Neuro-Oncology, 2004. 6(4): p. 456-456.
45. Packer R, Gajjar A, Vezina G, Langston D, Rorke L, Burger P, Robertson P, Murasko K, Armstrong D, Ris D, LaFond D, Boyer L, and **Sposto R**
Preliminary report of A9961: A phase III randomized study of craniospinal radiotherapy (CSRT) followed by one of two adjuvant chemotherapy regimens (CCNU, CPDD, VCR or CPM, CPDD, VCR) in children with newly diagnosed average-risk medulloblastoma (mb)
Neuro-Oncology, 2004. 6(4): p. 463-463.

46. Packer RJ, Gajjar A, Vezina G, Langston D, Rorke L, Burger P, Robertson-Murasko P, Armstrong D, Ris D, LaFond D, Boyer L, and **Sposto R**
Preliminary results of a prospective randomized study of "reduced" craniospinal radiotherapy followed by one of two adjuvant chemotherapy regimens for children with medulloblastoma: Children's Oncology Group study
Annals of Neurology, 2004. 56: p. S89-S90.
47. Packer RJ, Gajjar A, Vezina G, Langston J, Rorke L, Burger P, Robertson P, Murasko K, Armstrong D, Ris D, LaFond D, Boyer L, and **Sposto R**
cGy of craniospinal radiotherapy (CSRT) plus chemotherapy for children with "average-risk" medulloblastoma (MB): A prospective randomized children's oncology group study (A9961)
Neuro-Oncology, 2004. 6(4): p. 387-387.
48. Satwani P, Perkins S, Kinney M, Davenport G, **Sposto R**, Abromowitch M, and Cairo M
CD25 is highly expressed in childhood ALCL and may be an excellent target for denileukin difitox fusion protein
Cancer Biotherapy and Radiopharmaceuticals, 2004. 19(4): p. 539-539.
49. Trippett T, De Alarcon P, London W, **Sposto R**, Chen A, Gardner S, and Schwartz C
AHOD00P1, a pilot study of re-induction chemotherapy with ifosfamide, and vinorelbine (IV) in children with refractory/relapsed Hodgkin disease.
Blood, 2004. 104(11): p. 684a-685a.
50. Weisfeld-Adams JD, Murphy DM, Wisoff JH, **Sposto R**, Young D, and Finlay JL
The impact of extent of surgical resection of consensus-reviewed pediatric intracranial high-grade glioma on outcome: A report of the children's cancer group trial No. CCG-945
Neuro-Oncology, 2004. 6(4): p. 468-468.
51. Cairo M, Gerrard M, **Sposto R**, Auperin A, Pinkerton R, Michon J, Weston C, Perkins S, Raphael M, McCarthy K, and Patte C
52. Deletion of cranial irradiation and addition of systemic high dose methotrexate and intrathecal chemotherapy results in 70 4-yr. EFS in children and adolescents with CNS positive B-NHL: Results of International FAB/LMB 96 study
Annals of Oncology, 2005. 16: p. 62-62.
53. Chen A, Hess A, Gardner S, Trippett T, de Alarcon P, Guillerman R, Hogan S, Mitchell J, Gamis A, Massey V, Constine LS, Villaluna D, **Sposto R**, and Schwartz C
Cyclosporine, interferon-gamma, and interleukin-2 immunotherapy is tolerable and induces autoreactivity in patients with recurrent/refractory Hodgkin disease undergoing autologous stem cell transplantation with BEAM: A COG study.
Blood, 2005. 106(11): p. 590a-591a.
54. Goldman S, Gerrard M, **Sposto R**, Davenport G, Auperin A, Pinkerton R, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C, and Cairo MS
Excellent results in children and adolescents with isolated mature B-Acute lymphoblastic leukemia (B-ALL) (Burkitt): Report from the French-American-British (FAB) international LMB study FAB/LMB96.
Blood, 2005. 106(11): p. 72a-72a.

55. Miles R, Raphael M, McCarthy K, Wotherspoon A, Lones M, Cairo M, Patte C, Gerrard M, **Sposto R**, Auperin A, Weston C, and Perkins S
Diffuse large B-cell lymphomas in pediatric patients demonstrate a marked predominance of germinal center cell phenotype
Annals of Oncology, 2005. 16: p. 61-61.
56. Patte C, Gerrard M, Auperin A, Michon J, Pinkerton R, **Sposto R**, Weston C, Perkins S, Raphael M, McCarthy K, and Cairo M
Prognostic factors in childhood/adolescent B-cell lymphoma: Results of the international FAB/LMB 96 study
Annals of Oncology, 2005. 16: p. 63-63.
57. Poirel HA, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley P, Raphael M, Perkins S, McCarthy K, **Sposto R**, Weston C, Gerrard M, Cairo MS, Bernheim A, and Patte C
In pediatric mature B-cell non Hodgkin lymphoma (NHL), complex karyotype or del(13q) are linked prognostic factors in Burkitt lymphoma (BL) while 8q24/c-myc rearrangement is associated with a strong adverse effect in diffuse large B-cell lymphoma (DLBCL).
Blood, 2005. 106(11): p. 541a-541a.
58. Satwani P, Perkins S, Kinney M, Davenport V, **Sposto R**, Abromowitch M, and Cairo M
CD52 and CD25 are highly expressed in childhood non-Hodgkin's lymphoma and may be excellent targets for immunotherapy with alemtuzumab and/or denileukin diftitox, respectively
Annals of Oncology, 2005. 16: p. 133-133.
59. **Sposto R**, Kelly KM, Villaluna D, Gilman E, Pfistner B, and Diehl V
A comparison of toxicity and outcome following BEACOPP therapy in adolescents and young adults with Hodgkin's disease (HD) by pediatric and adult oncology cooperative groups.
Journal of Clinical Oncology, 2005. 23(16): p. 584s-584s.
60. Abromowitch M, **Sposto R**, Perkins S, Finlay J, and Cairo MS
Results of CCG-5941: Intensified multiagent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents.
Blood, 2006. 108(11): p. 161a-161a.
61. Ater J, Holmes E, Zhou T, Mazewski C, Roberts W, Booth T, Ettinger A, Freyer D, Jakacki R, Kadota R, Lazarus K, Pearce J, Pollack I, Prados M, **Sposto R**, Vezina G, Wisoff J, Yates A, and Packer R
Treatment of young children with progressive or symptomatic unresectable low-grade glioma with chemotherapy: Preliminary report from the Children's Oncology Group (COG) phase 3 protocol A9952
Neuro-Oncology, 2006. 8(4): p. 465-465.
62. Packer RJ, Jakacki R, Zhou T, Rorke-Adams LB, **Sposto R**, and Burger PC
Childhood medulloblastoma (MB): Incidence and significance of anaplasia
Annals of Neurology, 2006. 60: p. S112-S112.

63. Perentesis JP, Villaluna D, Davies SM, Zhai XW, Radloff GA, Weiner MA, **Sposto R**, and Kelly KM
Pharmacogenetic predictors of toxicity in dose-intensive therapy for pediatric advanced-stage Hodgkin's lymphoma.
Blood, 2006. 108(11): p. 33a-34a.
64. Perkins SL, Miles RR, Sarwani P, Kinney M, Davenport G, **Sposto R**, Abromowitch M, and Cairo MS
Expression of CD52, CD25, CD74, and CD80 in childhood NHL: Implications for targeted therapy
Cancer Biotherapy and Radiopharmaceuticals, 2006. 21(4): p. 403-403.
65. **Sposto R**, Raetz EA, Reynolds CP, and Gaynon PS
Multi-agent phase I trials in childhood acute lymphoblastic leukemia (ALL).
Blood, 2006. 108(11): p. 211b-211b.
66. Asgharzadeh S, Tu YX, Gonzalez-Gomez I, Finlay J, Seeger R, Ji LY, and **Sposto R**
Prognostic significance of gene expression profiles of medulloblastomas
Neuro-Oncology, 2007. 9(4): p. 560-560.
67. Ater J, Mazewski C, Roberts W, **Sposto R**, Zhou T, Freyer D, Jakacki R, Kadota R, Lazarus K, Packer R, Pearce J, Prados M, Ettinger A, Vezina G, Wisoff J, Yates A, and Pollack I
Phase 3 randomized study of two chemotherapy regimens for treatment of progressive low-grade glioma in young children: Preliminary report from the children's oncology group protocol A9952
Neuro-Oncology, 2007. 9(2): p. 204-204.
68. Cole PD, Trippett TM, Drachtman RA, DeAlarcon P, Chen L, **Sposto R**, and Schwartz CL
AHOD0321: A cog phase II study of weekly gemcitabine and vinorelbine in children with recurrent or refractory Hodgkin disease
Haematologica-the Hematology Journal, 2007. 92: p. 58-58.
69. Doorninck J, Abdueva D, **Sposto R**, Triche T, and Lawlor E
Variability in gene expression among ewing tumors with type 1 versus type 2 EWS-FLI-1 fusion proteins
Pediatric Blood & Cancer, 2007. 49(4): p. 439-440.
70. Finlay J, Tang R, Haley K, Siegel M, Gardner S, Allen J, Butturini A, Puccetti D, Cornelius A, Torkildson J, Ji LY, and **Sposto R**
The treatment of young children with malignant gliomas and diffuse intrinsic pontine gliomas (DIPG): Results of an irradiation-avoiding strategy, the "HEAD START" protocols 1991-2006
Neuro-Oncology, 2007. 9(4): p. 539-539.

71. Finlay JL, Sands S, Gardner S, Dunkel IJ, McGowage G, Kellie S, Diaz B, Abromowitch M, Termuhlen A, Olshefsky R, Cornelius A, Garvin J, Allen J, Miller D, Rosenblum M, Haley K, Grodman H, Atlas M, Ji L, and **Sposto R**
Nondisseminated medulloblastoma in children less than three years of age: Final report of the head start I and II protocols
Neuro-Oncology, 2007. 9(2): p. 190-191.
72. Ko RH, Ji L, **Sposto R**, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel N, Twist C, Eckroth E, Gaynon P, and Loh M
Retrospective survey of children treated for relapsed acute lymphoblastic leukemia (Complete Remission (CR) Rates): A report from the Therapeutic Advances in Childhood Leukemia (TACL) consortium
Blood, 2007. 110(11): p. 262a-262a.
73. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger P, Robertson P, LaFond D, Bayer L, Donahue B, Marymont M, Muraszko K, Langston J, and **Sposto R**
Final results of COG 9961: A prospective randomized study of 2340 cGy of craniospinal radiation therapy and adjuvant chemotherapy for average-risk medulloblastoma
Neuro-Oncology, 2007. 9(2): p. 191-191.
74. Poirel HA, Heerema NA, Swansbury J, Auperin A, Launay E, Sanger WG, Talley A, Raphael M, Perkins S, McCarthy K, **Sposto R**, Weston C, Gerrard M, Bernheim A, Cairo MS, and Patte C
Cytogenetic analysis of 238 pediatric mature B-cell non hodgkin lymphoma (NHL) cases from the randomized international FAB LMB96 trial identifies several patterns of chromosomal abnormality and new prognostic factors
Acta Clinica Belgica, 2007. 62(4): p. 249-249.
75. Schwartz CL, Constine LS, London WB, **Sposto R**, Friedman D, Tebbi CK, Mendenhall NP, Villaluna D, de Alarcon PA, and Chauvenet A
Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without compelling evidence - Reply
Journal of Clinical Oncology, 2007. 25(21): p. 3180-3180.
76. Schwartz CL, Constine LS, London WB, **Sposto R**, Friedman DL, Tebbi CK, Mendenhall N, Chen AR, De Alarcon PA, Villaluna D, and Chauvenet AR
Targeted therapies: Cui prodest?
Journal of Clinical Oncology, 2007. 25(29): p. 4691-4692.
77. Schwartz CL, Constine LS, London WB, **Sposto R**, Friedman DL, Tebbi CK, Mendenhall N, Chen AR, De Alarcon PA, Villaluna D, and Chauvenet AR
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without evidence - Reply
Journal of Clinical Oncology, 2007. 25(29): p. 4690-4691.
78. Zacharoulis S, Ji L, Pollack IF, Duffner PK, Geyer JR, Grill J, Schild SE, Jaing TH, Massimino M, Finlay JL, and **Sposto R**
Metastatic ependymoma: A multi-institutional retrospective analysis of prognostic factors
Neuro-Oncology, 2007. 9(2): p. 218-218.

79. Allen J, Donahue B, Mehta M, Miller D, Rorke L, Jakacki R, Robertson P, **Sposto R**, Holmes E, Vezina G, Muraszko K, Puccetti D, and Prados M
Final report of CCG protocol 9931 for high-risk medulloblastoma/PNET: Neoadjuvant chemotherapy followed by hyperfractionated craniospinal radiotherapy
Neuro-Oncology, 2008. 10(3): p. 479-479.
80. Finlay J, Krieger M, Nasta A, Gonzalez-Gomez I, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, McComb G, Olch A, Britt B, **Sposto R**, and Lavey R
Treatment of primary CNS germinomatous germ cell tumors (GCT) with chemotherapy prior to reduced-dose ventricular field irradiation: The Childrens Hospital Los Angeles experience 2003-2007
Neuro-Oncology, 2008. 10(3): p. 421-421.
81. Flores-Delgado G, Liu CWY, **Sposto R**, and Berndt N
A limited screen for protein interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis (vol 6, pg 1165, 2007)
Journal of Proteome Research, 2008. 7(3): p. 1352-1352.
82. Gozali A, Shane L, McComb G, Krieger M, Gonzalez-Gomez I, Gilles F, Villablanca J, Erdreich-Epstein A, Lavey R, **Sposto R**, and Finlay J
Choroid plexus tumors and the Li-Fraumeni syndrome: The childrens hospital Los Angeles (CHLA) experience 1991-2006
Neuro-Oncology, 2008. 10(3): p. 500-501.
83. Haley K, Dhall G, Ji L, **Sposto R**, and Finlay J
Unexpected morbidities and mortalities in young children during induction chemotherapy, enrolled on the "Head Start III" protocol for newly diagnosed embryonal tumors
Neuro-Oncology, 2008. 10(3): p. 423-424.
84. Lowe EJ, **Sposto R**, Perkins SL, Gross T, Finlay J, and Abromowitch M
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941
Annals of Oncology, 2008. 19: p. 138-139.
85. Messinger YH, Gaynon PS, Raetz E, Hutchinson R, DuBois S, Bender JG, **Sposto R**, van der Giessen J, Eckroth E, and Bostrom BC
Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.
Blood, 2008. 112(11): p. 670-670.
86. O'Neil S, Finlay J, Azoff J, **Sposto R**, Sands S, Steinlauf S, Nasta A, Krieger M, McComb G, Olch A, and Robert L
Neurocognitive outcomes in pediatric patients with CNS germinoma treated with chemotherapy prior to irradiation
Neuro-Oncology, 2008. 10(3): p. 420-420.

87. Patel N, Showman A, Haley K, Siegel M, Gardner S, Hukin J, Sullivan M, Cornelius A, Mccowage G, Allen J, Ji LY, **Sposto R**, and Finlay J
The treatment of young children with high-grade gliomas (HGGs) and diffuse intrinsic brainstem gliomas (DIBSGs): Results of an irradiation-avoiding strategy, the "Head Start" protocols 1991-2007
Neuro-Oncology, 2008. 10(3): p. 427-427.
88. Robison N, Gonzalez-Gomez I, Ji LY, Tu YX, Joo W, Finlay J, **Sposto R**, and Asgharzadch S
Prognostic significance of forkhead box G1 expression in pediatric medulloblastoma
Neuro-Oncology, 2008. 10(3): p. 487-487.
89. Serowka K, Chiu Y, Gonzalez-Gomez I, Gilles F, Mccomb G, Krieger M, Lavey R, Dhall G, Britt B, Ji LY, **Sposto R**, and Finlay J
CNS tumors in the first 6 months of life: The Childrens Hospital Los Angeles Experience, 1979-2005
Neuro-Oncology, 2008. 10(3): p. 434-434.
90. Wells EM, Khademian P, Walsh KS, **Sposto R**, Vezina G, Keating RF, and Packer RJ
Neuroradiographic features of patients with the cerebellar mutism syndrome: A longitudinal MRI study
Annals of Neurology, 2008. 64: p. S87-S87.
91. Cairo MS, **Sposto R**, Fan J, Gerrard M, Auperin A, Pinkerton R, McCarthy K, Raphael M, Harrison L, Goldman S, and Patte C
SURVIVAL IN CHILDREN AND ADOLESCENTS (C plus A) WITH MATURE B-NHL PROGRESSING OR RELAPSING FROM TREATMENT ON FAB/LMB 96: TUMOR BURDEN AND TIME TO RELAPSE ARE POOR PROGNOSTIC FACTORS
Pediatric Blood & Cancer, 2009. 53(5): p. 855-855.
92. Cairo MS, **Sposto R**, Gerrard M, Waxman I, Goldman S, Auperin A, Pinkerton R, Raphael M, McCarthy K, Perkins SL, and Patte C
Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial
Journal of Clinical Oncology, 2009. 27(15): p. -.
93. Finlay J, Dhall G, Haley K, Erdreich-Epstein A, Gonzalez I, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Ji LY, and **Sposto R**
Irradiation-Avoiding Strategy for Treatment of Young Children with Central Nervous System Atypical Teratoid/Rhabdoid Tumors: The Head Start Experience, 1991-2009
Pediatric Blood & Cancer, 2009. 53(5): p. 728-729.
94. Finlay J, Krieger M, Nasta A, Gonzalez I, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Britt B, Gilles F, McComb G, Olch A, O'Neil S, **Sposto R**, and Lavey R
Treatment of Primary Cns Germinomatous Germ Cell Tumors (Gct) with Chemotherapy Prior to Reduced-Dose Ventricular Field Irradiation: The Childrens Hospital Los Angeles Experience 2003-2007
Neuro-Oncology, 2009. 11(2): p. 232-232.

95. Finlay JL, Haley K, Dhall G, Fangusaro J, Chi S, Allen J, Sands S, **Sposto R**, and Gardner S
Management of Young Children Newly Diagnosed with Cns Embryonal Tumors: 18 Years of Three Sequential Irradiation-Avoiding Chemotherapy Studies-the "Head Start" Protocols
Neuro-Oncology, 2009. 11(6): p. 875-876.
96. Gerrard M, Waxman I, **Sposto R**, Auperin A, Harrison L, Pinkerton R, Perkins SL, McCarthy K, Raphael M, Patte C, Cairo MS, and Trial FL
Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial
Journal of Clinical Oncology, 2009. 27(15): p. Cp50-U415.
97. Gruber T, Chang MS, **Sposto R**, and Muschen M
Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution of BCR-ABL1-Driven B Cell Lineage Acute Lymphoblastic Leukemia
Blood, 2009. 114(22): p. 80-80.
98. Song LP, Asgharzadeh S, Salo J, Engell K, Wu HW, **Sposto R**, DeClerck YA, Seeger RC, and Metelitsa LS
NKT Cells in Neuroblastoma
Journal of Pediatric Hematology Oncology, 2009. 31(4): p. 241-242.
99. Davidson TB, Gorralum F, Ji L, Engell K, **Sposto R**, Asgharzadeh S, and Erdreich-Epstein A
Insulin-Like Growth Factor Binding Protein 2 (Igfbp2) Promotes Growth of Medulloblastoma Cell Lines
Neuro-Oncology, 2010. 12: p. 12-13.
100. Finlay JL, Haley K, Dhall G, Gardner S, Allen J, Cornelius A, Olshefski R, Garvin J, Pradhan K, Ettl M, Goldman S, Atlas M, Thompson S, Hirt A, Hukin J, Comito M, Bertolone S, Torkildson J, Joyce M, Moertel C, Letterio J, Kennedy G, Walter A, Ji LY, and **Sposto R**
Head Start III: A Prospective Multinational Protocol for Newly Diagnosed Cns Embryonal Tumors (Medulloblastoma and Other Primitive Neuroectodermal Tumors Vertical Bar Pnet Vertical Bar) of Young Children with an Irradiation-Avoiding Strategy. First Report of Response to and Outcome of Induction Chemotherapy
Neuro-Oncology, 2010. 12: p. 69-70.
101. O'Neil SH, Azoff J, Buranahirun C, Dhall G, Panigrahy A, Borchert M, Khatua S, Ji LY, **Sposto R**, and Finlay J
Neurocognitive Outcomes in Pediatric and Adolescent Patients with Central Nervous System Germinoma Treated with a Strategy of Chemotherapy Followed by Reduced-Dose and Volume Irradiation
Neuro-Oncology, 2010. 12: p. 58-58.

102. Parekh C, Sahaghian A, Scholes J, Ge S, Zhu Y, Ji L, **Sposto R**, and Crooks G
Regulated Expansion of Human Myelo-Erythroid Progenitors Using a Ligand Inducible System
Experimental Hematology, 2010. 38(9): p. S54-S54.
103. Antony R, Gardner S, Patel M, Wong KE, Britt B, Dhall G, Grimm J, Krieger M, McComb G, Gilles F, **Sposto R**, and Finlay JL
Recurrent Intracranial Ependymoma as Chronic Disease: A Retrospective Analysis
Neuro-Oncology, 2011. 13: p. 99-99.
104. Erdreich-Epstein A, Ren XH, Zhou H, Schur M, Xu JY, Scott J, Ji LY, **Sposto R**, and Asgharzadeh S
A Gene with Inhibitory Function(S) in Brain Tumors
Neuro-Oncology, 2011. 13: p. 136-137.
105. Erdreich-Epstein A, Zhou H, Ren XH, Davidson TB, Schur M, Ji LY, **Sposto R**, and Asgharzadeh S
Pid1 Expression Correlates with Pfs (Medulloblastoma) and Os (Glioma) and Inhibits Growth of Brain Tumor Cell Lines
Neuro-Oncology, 2011. 13: p. 103-103.
106. Espinoza J, Haley K, Patel N, Dhall G, Gardner S, Jeffrey A, Torkildson J, Cornelius A, Rassekh R, Bedros A, Ettl M, Garvin J, Pradhan K, Corbett R, Sullivan M, McGowage G, Puccetti D, Stein D, Jasty R, Ji LY, **Sposto R**, and Finlay JL
Final Report on Outcome of Children with Newly Diagnosed High-Grade Glioma (Hgg) Treated with Multi-Drug Induction Chemotherapy Followed by Consolidative Myeloablative Chemotherapy and Autologous Hematopoietic Progenitor Cell Rescue (Auhpcr) on the "Head Start" Ii and Iii Protocols
Neuro-Oncology, 2011. 13: p. 98-99.
107. Liu Y, Sheard M, Wu HW, **Sposto R**, June C, Kelly S, Cooper L, Lee D, and Seeger R
Expansion and Activation of Cytotoxic Human Natural Killer Cells from Peripheral Blood for Neuroblastoma Immunotherapy
Pediatric Blood & Cancer, 2011. 57(5): p. 739-739.
108. Venkatramani R, Haley K, Gilles F, **Sposto R**, Ji LY, Olshefski R, Garvin J, Tekautz T, Kennedy G, Rassekh R, Moore T, Gardner S, Allen J, Shore R, Moertel C, Atlas M, Lasky J, and Finlay J
Outcome of Infants and Young Children with Newly Diagnosed Ependymoma Treated on "Head Start" Iii Protocol
Neuro-Oncology, 2011. 13: p. 95-95.
109. Venkatramani R, Wang L, Malvar J, **Sposto R**, Malogolowkin M, and Mascarenhas L
Tumor Necrosis Predicts Survival Following Neo-Adjuvant Chemotherapy for Hepatoblastoma
Pediatric Blood & Cancer, 2011. 56(6): p. 901-901.

SCIENTIFIC MEETINGS.

Invited Speaker: "Parametric Cure Models in Pediatric Cancer", at Conference on Mathematical Models in Medical and Health Sciences, Vanderbilt University
May 28-31, 1997.

Session Organizer: "Cure Models and Clinical Research", at Eastern North American Region of the Biometrics society (ENAR) meeting, Memphis, Tennessee
1997: p. March 25.

Invited Speaker: "A Strategic View of Randomized Trial Design in Low-Incidence Pediatric Cancer", Workshop on "Clinical Trials in Rare Conditions, at Society for Clinical Trials, Atlanta, GA
May 19, 1998.

Invited Speaker: "Risk Stratification in Pediatric Cancer", Mini-symposium on "Statistical Challenges in Pediatric Research", at International Society for Clinical Biostatistics, Trento, Italy
September 8, 2000.

Invited Speaker: "Clinical Trials Design in Pediatric Oncology" at Workshop on Pediatric Oncology Drug Development, Center for Drug Evaluation and Research, FDA
July 18, 2002.

Invited Speaker: "Pediatric Cooperative Group Research in COG", UKCCSG Meeting of International Statisticians, Leicester, UK
May 29-30, 2003.

Invited speaker: "Design of Phase I and II Trials for New Therapies for Neuroblastoma", workshop on Methods for Clinical Trials at Advances in Neuroblastoma Research Meeting
May 20, 2006.

Invited Speaker: "Design of Clinical Trials for Pediatric Cancers", at Statistical Symposium of the Society of Clinical and Biostatistical Research, Chuo University, Tokyo, Japan
December 16, 2006.

Invited Speaker: "System and Logistics for Clinical Trials for Pediatric Oncology in the U.S.A.", at Statistical Symposium of the Society of Clinical and Biostatistical Research, Chuo University, Tokyo, Japan
December 16, 2006.

Invited speaker: "Basic Concepts of Phase II Trial Design", workshop on Clinical Trial Design: The Challenges of Middle Development (Phase II), AACR
April 17, 2010.

SCIENTIFIC PRESENTATIONS.

"Biostatistics Core", at 1st Annual External Scientific Review of the Pediatric Brain Tumor Research Program, Los Angeles, CA
October 9, 2006.

"Are there 'optimal' prognostic risk groups? " at CHLA Division of Hematology/Oncology Grand Rounds
May 31, 2006.

"Biostatistical considerations and endpoints in HS III", at Headstart Investigators Meeting, Los Angeles, CA
October 4, 2006.

"Are there 'optimal' prognostic risk groups? " at Children's Oncology Group Groupwide Symposium: Statistical Methods and Children's Oncology Group Research
October 5, 2006.

"Summary of Sarcoma SPECS Bioinformatics Meeting" at SPECS investigators meeting, Los Angeles, CA
November 13-14, 2006.

Invited Speaker: "Risk/Benefit Analysis of Targeted Treatment Strategies in Childhood Cancer" at Contemporary Clinical Trials Seminar Series, Department of Biostatistics in the Division of Information Sciences, City of Hope
July 18, 2007.

"Early Phase Trial Design in Pediatric Cancer. It is time to break with the past! (Or is it?) " at CHLA Division of Hematology/Oncology Grand Rounds
October 20, 2010.